The pharmaceutical company Moderna started the last, longest step in the process of testing its COVID-19 vaccine candidate at the end of July – a Phase 3 clinical trial. It’s an enormous undertaking: their goal is to recruit 30,000 people, inject some of them with an experimental vaccine and then follow each and every one of them to see how many contract the coronavirus and how many do not.
I wrote a blog post over the weekend that has generated tremendous pushback, including an op-ed in the New York Times as well as thousands of comments on Twitter. In my previous post, I suggested that while we’re pursuing Phase 3 testing of several promising Covid-19 vaccines, we could simultaneously offer those same, unapproved vaccines to a wider community of volunteers, as long as those volunteers were fully informed.
Scientists need to show us the data. And that’s exactly what they’re working on. By Dr. Dean is an assistant professor of biostatistics at the University of Florida. Coronavirus vaccines are rapidly advancing through the development pipeline. The University of Oxford’s vaccine is in large trials in Britain, Brazil and South Africa.
The confident depiction by politicians and companies that a vaccine is imminent and inevitable may give people unrealistic beliefs about how soon the world can return to normal – and even spark resistance to simple strategies that can tamp down transmission.
As countries race to find a coronavirus cure, Germany’s research minister has said any vaccine was unlikely to be available until the middle of 2021 at the earliest. “We should not expect a miracle,” Anja Karliczek told a news conference on Wednesday.
So much hope is riding on a breakthrough, but a vaccine is only the beginning of the end. Editor’s Note: The Atlantic is making vital coverage of the coronavirus available to all readers. Find the collection here. Nearly five months into the pandemic, all hopes of extinguishing COVID-19 are riding on a still-hypothetical vaccine.
Don’t hold your breath for a coronavirus vaccine. Here are the 7 biggest challenges we still need to overcome.
Drugmakers, scientists, and governments are racing to develop a coronavirus vaccine at unprecedented speeds. It seems possible, or even likely, that a vaccine could be available by early 2021. But there are countless obstacles to creating a successful vaccine and ensuring people take it, including public skepticism about a vaccine’s safety and the fair and equitable distribution of shots.
WASHINGTON – Americans struggling through the worsening coronavirus outbreak got some rare good news this week as researchers delivered encouraging updates about potential vaccines. Even Dr. Anthony Fauci, whose gloomy warnings have frustrated President Donald Trump, has sounded consistently enthusiastic about the prospects.
How much should it cost the average American to get a COVID-19 vaccine shot in the arm? Although a vaccine is still months if not longer away, billions of tax dollars are being spent to rapidly research, develop, manufacture and distribute several candidates.
Wharton finance professor Jeremy Siegel expects a game changer. He predicts a coronavirus vaccine is closer than the market thinks. “We’ve had almost no setbacks in the schedule developing the vaccine, and I think that’s where upside surprises can occur,” Siegel told CNBC’s ” Trading Nation” on Tuesday.
‘Vaccine nationalism’ could lead to the coronavirus devastating public health and the economy, experts warn
“Vaccine nationalism” is turning the search for a Covid-19 cure into an arms race, which will ultimately damage the economy and public health, experts have warned. Analysts at Eurasia Group speculated that tension over a vaccine would heat up over the summer, predicting a battle for access that will stretch into 2021 or 2022.